【藥品性質提示】 根據 2019 AGS Beers Criteria，本藥品為【潛在不適當用藥 (PIM)】，不建議用於昏厥或 CKD >stage3 之老年人。

高血壓 (ACEI) Hypertension; Prevent congestive heart failure in patients with diabetic nephropathy, retinopathy, congestive heart failure, myocardial infarction

Captopril is an oral antihypertensive agent that blocks the conversion of angiotensin I to angiotensin II by inhibiting angiotensin I-converting enzyme (ACE), a peptidyldipeptide carboxy hydrolase. It exerts its effect in hypertension and heart failure by suppressing the renin-angiotensin system

Ttime to peak concentration, about 1 h; Bioavailability: approximately 75%; Effect of food: reduces absorption by about 30% to 40%. Distribution: Protein binding: approximately 25% to 30%; Excretion: Renal: more than 95%, 40% to 50% unchanged; Dialyzable: yes (hemodialysis, Adult), unknown (hemodialysis, neonates and children), no (peritoneal); Elimination Half Life: less than 3 h.

Hypersensitivity to captopril other ACEIs, history of angioedema, bilateral renal artery stenosis

C during the first trimester, and D during the second and third trimester

Safe; the level of captopril in milk is low, the milk/plasma ratio is 0.012. No adverse effect has been reported.

Skin rash, pruritus, taste disturbance, proteinuria (renal disease history); serum potassium concentration may be raised.

Usual dose: 25-150mg TID, 1 hour AC; Maximum dose: 450 mg/day

Usual dose: 1mg/kg/day; Maximum dose: 6 mg/kg/day

Renal impairment: initial dose should be reduced; titration should be in smaller increments